why choose us

First received: February 17, 2023

Clinical Trial: Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neuroendocrine Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Brief Summary: This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET).First described in the pancreas in 2017, the classification was broadened to include gastrointestinal tract tumors in 2019.Recent data suggest an equivalent subtype exists in the lungs (NEC with carcinoid morphology).WD G3 NETs can occur de novo as well as the result of grade progression over time.This is a single arm, multi-site, Phase II study in biomarker…

Read more